Could Data Backing Implant Shift Treatment?

This study, our extensive clinical data, and the increasing number of iFuse procedures performed annually demonstrate that there is a shift in how physicians understand SI joint dysfunction and its role in causing chronic pain.” Dunn reported that more than 37,000 iFuse procedures have been performed by more 1800 surgeons in the United States and 33 other countries around the world. “There is a significant, addressable, and growing market opportunity for iFuse: we believe there are 279,000 eligible patients each year in the United States alone, translating to a $2.7 billion market opportunity. SI-BONE also has strong and often exclusive reimbursement coverage, which is a significant contributor to our growth. This includes positive coverage decisions from 45 of the 65 largest private payers as well as 26 commercial coverage policies (~46M covered lives) exclusive to iFuse. We expect this trend to continue since no other competitive company has the clinical data to support equivalent claims.” SI-BONE completed its IPO in October 2018 and plans to use the proceeds to fuel growth. “We plan to use this recent capital infusion to aggressively invest in growth over the next 5 – 10 years, by expanding sales and marketing efforts, educating and training thousands of new surgeons, and investing in other product development and other market expansion opportunities,” Dunn said. Th...
Source: MDDI - Category: Medical Devices Authors: Tags: Orthopedics Source Type: news